Wellesley, Mass. – According to a new technical market research report, BIOLOGIC IMAGING REAGANTS: TECHNOLOGIES AND GLOBAL MARKETS (BIO064B), from BCC Research (www.bccresearch.com), the global market for biologic imaging reagents was valued at $9.4 billion in 2011 and is expected to reach $9.9 billion in 2012. Total market value is expected to reach nearly $14.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 7.8%.
The market for biologic imaging reagents can be broken down into three main segments: contrast reagents, optical reagents, and nuclear reagents.
The segment made up of contrast reagents should reach a value of $4.6 billion in 2012 and $5.3 billion in 2017, a CAGR of 2.8%.
As a segment, optical reagents are expected to have a value of nearly $3.5 billion in 2012 and $4.9 billion in 2017, a CAGR of 7.3%.
The nuclear reagents segment should total nearly $1.9 billion in 2012 and $4.2 billion in 2017, a CAGR of 18%.
Biologic imaging reagents comprise an extremely diverse range of technologies and applications. Imaging reagents are core, enabling technologies in molecular biology, biotechnology, pharmaceuticals, and medicine. Reagents help to detect key molecular and biological processes, and they function as biomarkers in the detection and diagnosis of diseases. Besides imaging reagents themselves, ancillary technologies are important to this industry, including nanobiotechnology, supramolecular chemistry, monoclonal antibodies, nanotechnology, and protein engineering. These technologies add targeting and chelating functions to the imaging reagent.
In-vitro applications of imaging reagents include molecular biology assays such as polymerase chain reaction (PCR) or fluorescence activated cell sorting (FACS). In these applications, imaging reagents are used as labels or tags to determine the presence or activity of a biomolecule. Reagents for these applications include nanoparticles such as quantum dots (QDs), and fluorescent dyes, or proteins. In many instances, these reagents are conjugated to antibodies or other targeting molecules.
This report will help its readers:
This report will be valuable to many industry participants, including the following:
Biologic Imaging Reagents: Technologies and Global Markets( BIO064B )
Publish Date: January 2013
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, Telephone: 866-285-7215; Email: firstname.lastname@example.org as the source and publisher. Thank you.